PPARA and metabolic dysfunction-associated steatotic liver disease: This Ppar(α)-driven role in lipid homeostasis in LSECs also implies that Ppar(α) agonists that have been proposed for MASLD treatment because of their role in hepatocytes39may offer additional benefit through their action on liver endothelium.